Results 121 to 130 of about 2,151,759 (386)

Biocatalytic Nanoregulators Restore Joint Redox‐Immune Homeostasis in Rheumatoid Arthritis

open access: yesAdvanced Science, EarlyView.
Mesenchymal stem cell‐derived extracellular vesicles (EVs) coat ruthenium‐loaded metal‐organic frameworks (Ru@ZrMOF), creating a targeted therapeutic (Ru@ZrMOF/EVs). This platform scavenges ROS, generates oxygen, and polarizes macrophages from M1 to M2, alleviating inflammation, inhibiting pannus, promoting cartilage repair, and downregulating HIF‐1α ...
Xingheng Wang   +7 more
wiley   +1 more source

PD‐1 Inhibits CD4+ TRM‐Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC

open access: yesAdvanced Science, EarlyView.
CD4+ tissue‐resident memory T cells (TRMs) in non‐small cell lung cancer recruit conventional type 1 dendritic cells via XCL1‐XCR1 signaling, orchestrating antitumor immunity. The costimulatory molecule JAML is essential for this process. PD‐1 blockade restores JAML expression and cDC1 mobilization, while JAML agonists synergize with anti‐PD‐1 therapy,
Zheyu Shao   +16 more
wiley   +1 more source

Computational models of the pulmonary circulation: Insights and the move towards clinically directed studies

open access: yesPulmonary Circulation, 2011
Biophysically-based computational models provide a tool for integrating and explaining experimental data, observations, and hypotheses. Computational models of the pulmonary circulation have evolved from minimal and efficient constructs that have been ...
M. Tawhai, A. Clark, K. Burrowes
semanticscholar   +1 more source

Short- and long-term experience in pulmonary vein segmental ostial ablation for paroxysmal atrial fibrillation* [PDF]

open access: yes, 2006
Introduction: Segmental ostial pulmonary vein isolation (PVI) is considered a potentially curative therapeutic approach in the treatment of paroxysmal atrial fibrillation (PAF).
Aichinger, J   +4 more
core   +1 more source

Regulating Tumor Metabolic Reprogramming with Biomimetic Co‐Delivery of Simvastatin and Kynureninase for Immunotherapy

open access: yesAdvanced Science, EarlyView.
After the intravenous injection of biomimetic and pH/ROS‐responsive PTSK@CRM, the nanoparticles can be accumulated in tumors and release Sim and KYNase to inhibit the tumor growth, regulate the metabolism of cholesterol and Kyn, and reverse the immunosuppressive tumor microenvironment.
Jiaxin Yin   +6 more
wiley   +1 more source

Clinical outcomes of upfront combination therapy for portopulmonary hypertension

open access: yesInternational Journal of Cardiology. Cardiovascular Risk and Prevention
Background: Limited data exists on upfront combination therapy for portopulmonary hypertension. We evaluated the clinical efficacy, long-term outcomes, and safety of upfront combination therapy in patients with portopulmonary hypertension.
Takatoyo Kiko   +8 more
doaj   +1 more source

Extracellular Vesicle‐Delivered tRF‐His‐GTG‐1 Reprograms Neutrophil Lipophagy and Triggers Inflammation in COVID‐19

open access: yesAdvanced Science, EarlyView.
This study identifies platelet‐derived extracellular vesicles as key immunometabolic regulators in COVID‐19. The delivery of tRF‐His‐GTG‐1 to neutrophils activates TLR8mTOR signaling, disrupts lipophagy, and amplifies NET‐mediated inflammation. Importantly, targeting this axis restores neutrophil homeostasis, offering a potential therapeutic strategy ...
Tsai‐Ling Liao   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy